David A. Ricks
pharmaceutical executive
11 stories
18 quotes
It's a really strong start to the year for Lilly … it's hard to think of a time that we've been in a better position than this,
- Lilly CEO Dave Ricks said in an interview on CNBC's "Squawk Box."CNBCcnbc.com/2026/08…
I think an upside beat in a pretty big way our own expectations, but also the Street's with Mounjaro global adoption,
- Ricks saidCNBCcnbc.com/2026/08…
We're really pleased with the start; it's accelerating as we speak,
- Ricks saidCNBCcnbc.com/2026/08…
It’s an open-source, federated model, so that the cost to use it is participating with your data,
- Ricks said, addingIrish Timesirishtimes.com/technology/2026…
We showed what's possible, which is meaningful: Almost half the people lose more than 30% of their body weight,
- Ricks saidCNBCcnbc.com/2026/06…
We have to prove that in this pilot and prove cost effectiveness and then kind of reset what we expect from our health insurance, which is obesity care should be health care,
- Ricks saidCNBCcnbc.com/2026/06…
Earlier
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
CNBCcnbc.com/2026/08…Alex Knapp is a Forbes senior editor covering healthcare and science
Forbes UKforbes.com/sites/innovationrx…Eli Lilly deploys weight-loss cash on ‘App Store’ for scientists
Irish Timesirishtimes.com/technology/2026…Drugmakers race to find a place in the next wave of obesity drugs
CNBCcnbc.com/2026/06…The recently published study evaluated the efficacy and safety of a once-weekly, 9‑milligram dose of mazdutide, which was developed by domestic company Innovent Biologics, in treating obesity among Chinese adults
China Dailychinadaily.com.cn/a/202606…Weight-loss drug developers line up to tap lucrative market as competition heats up
Reutersreuters.com/business/healthcar…Shares of Eli Lilly (LLY) jumped nearly 5% in pre-market trading, approaching record highs on Monday, after strong data for Retatrutide and Foundayo presented at the American Diabetes Association meeting reinforced confidence in the company’s GLP-1 drug portfolio
Asianet Newsablenewsable.asianetnews.com/marke…US FDA proposes excluding weight-loss drugs from compounding list
Reutersreuters.com/business/healthcar…If finalized, the move could impact telehealth firms that rely on outsourcing facilities to produce these drugs in bulk, while bolstering Novo and Lilly’s efforts against unauthorized versions that are eating into sales of their blockbuster treatments
NBC Newsnbcnews.com/health/health…Lilly Boosts Sales View to $85 Billion on Obesity-Drug Surge
Bloomberg Newsbloomberg.com/news/articles…Eli Lilly profits more than double as weight-loss drug sales soar
Financial Timesft.com/content/527fb779…Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
CNBCcnbc.com/2026/04…Lilly's once-daily oral weight-loss drug, Foundayo, was launched earlier this month and was prescribed 3,707 times in the U.S. in the week ended April 17, below analysts' expectations closer to around 8,000
Reutersreuters.com/business/healthcar…New weight-loss pill hits the market, promising 'greater flexibility'
Fox Newsfoxnews.com/health/new…The US Food and Drug Administration on Wednesday approved the second GLP-1 pill for weight loss, adding another option to a rapidly growing arsenal of obesity therapies
CNNcnn.com/2026/04…Trump to Unveil ‘TrumpRX’ Website for Discounted Drug Purchases
Bloomberg Newsbloomberg.com/news/articles…The White House’s new TrumpRx platform launched Thursday, pledging dramatic prescription label price cuts for uninsured Americans
Los Angeles Timeslatimes.com/world/nation…The disruptive force of weight loss drugs: How GLP-1s do more than shed pounds
The Independentindependent.co.uk/news/world…GLP-1s, which help treat type 2 diabetes and can also help patients lose weight, have been a game-changer
Newsweeknewsweek.com/medicare/coverage…Marks & Spencer launches ‘nutrient dense’ range for people on weight-loss jabs
Guardiantheguardian.com/business/2025…Following a challenging year that saw its market capitalisation drop by nearly $400 billion from its mid-2024 peak, the pharma firm received a critical boost on 22 December 2025 with the FDA approval of the first once-daily Wegovy pill (25 mg oral semaglutide)
International Business Timesibtimes.com/novo/nordisks…